Crackdown on 20 pharma units across Himachal Pradesh

Shimla, Dec 11 (UNI) In a major enforcement action, the Himachal Pradesh Drug Control Administration along with the police conducted surprise and simultaneous raids on 20 pharmaceutical manufacturing units across the state.
The operation, carried out on Wednesday, covered industrial areas in Sirmaur (Nahan), Una, Kangra, and Solan districts.
State Drug Controller Manish Kapoor confirmed the development, explaining that the drive was part of a statewide operation targeting units already issued stop-manufacturing orders for violations under the Drugs and Cosmetics Act, 1940. The recent action against three units—Biological, Shivam, and MC Jain in the Kala Amb industrial area was also part of this coordinated effort.
During the inspections, authorities did not find ongoing production at any of the 20 units. However, evidence recovered from four locations indicated that manufacturing activities might have continued despite official prohibitory orders. According to the drug controller, this finding is serious and could lead to strict punitive measures.
The DCA has initiated proceedings under the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945. Dr. Kapoor said the administration will not tolerate any violations and warned that firms found defying orders will face stringent action. He added that a detailed investigation is now under way to verify the extent of the suspected violations.
Kapoor also acknowledged the role of the police department, stating that the operation reflects the state government’s commitment to curbing illegal activities in the pharmaceutical sector. He said similar enforcement actions will continue to ensure full compliance and protect public health.
The crackdown comes at a time when the pharmaceutical industry in Himachal Pradesh is under increased scrutiny due to repeated failures of drug samples and rising concerns about regulatory oversight. Authorities say the latest raids demonstrate a renewed effort to enforce discipline and restore confidence in the state’s drug manufacturing sector.

Leave a Reply